Evidence map›Paper›PMID 33391258›Full record

ArticleFrontiers in immunology2020

Augmenting E Protein Activity Impairs cDC2 Differentiation at the Pre-cDC Stage.

Sandra Bajana, Kevin Thomas, Constantin Georgescu, Ying Zhao, Jonathan D Wren, Susan Kovats, Xiao-Hong Sun

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sandra BajanaProgram in Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Kevin ThomasProgram in Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Constantin GeorgescuProgram in Genes and Human Diseases, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Ying ZhaoProgram in Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Jonathan D WrenProgram in Genes and Human Diseases, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Susan KovatsProgram in Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Xiao-Hong SunProgram in Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Oklahoma Medical Research Foundation · US

Funding

Understanding connective tissue development and disease with PDGFR-driven..... P20GM103636 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2013 to 2023
$26.9M
IRF4-Mediated Regulation of Lung Dendritic Cells During Viral InfectionR01HL119501 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KOVATS, SUSAN · 2014 to 2017
$1.7M
NHLBI NIH HHS R01 HL119501NIGMS NIH HHS P20 GM103636
6 · The paper itself

Abstract

Dendritic cell (DC) specification and differentiation are controlled by a circuit of transcription factors, which regulate the expression of DC effector genes as well as the transcription factors themselves. E proteins are a widely expressed basic helix-loop-helix family of transcription factors whose activity is suppressed by their inhibitors, ID proteins. Loss-of-function studies have demonstrated the essential role of both E and ID proteins in different aspects of DC development. In this study, we employed a gain-of-function approach to illustrate the importance of the temporal control of E protein function in maintaining balanced differentiation of conventional DC (cDC) subsets, cDC1 and cDC2. We expressed an E protein mutant, ET2, which dimerizes with endogenous E proteins to overcome inhibition by ID proteins and activate the transcription of E protein targets. Induction of ET2 expression at the hematopoietic progenitor stage led to a dramatic reduction in cDC2 precursors (pre-cDC2s) with little impact on pre-cDC1s. Consequently, we observed decreased numbers of cDC2s in the spleen and lung, as well as in FLT3L-driven bone marrow-derived DC cultures. Furthermore, in mice bearing ET2, we detected increased expression of the IRF8 transcription factor in cDC2s, in which IRF8 is normally down-regulated and IRF4 up-regulated. This aberrant expression of IRF8 induced by ET2 may contribute to the impairment of cDC2 differentiation. In addition, analyses of the transcriptomes of splenic cDC1s and cDC2s revealed that ET2 expression led to a shift, at least in part, of the transcriptional profile characteristic of cDC2s to that of cDC1. Together, these results suggest that a precise control of E protein activity is crucial for balanced DC differentiation.

Indexed as

Cell DifferentiationAnimalsBasic Helix-Loop-Helix ProteinsCells, CulturedDendritic CellsGene Regulatory NetworksHematopoietic Stem CellsInterferon Regulatory Factor-4Interferon Regulatory Factor-8Interferon Regulatory FactorsLungMice, TransgenicMutationPhenotypeSpleenTranscriptomeBasic Helix-Loop-Helix ProteinsInterferon Regulatory Factor-4Interferon Regulatory Factor-8Interferon Regulatory FactorscDC1cDC2E proteinIRF4IRF8pre-cDC

Identifiers

PMID33391258
PMCPMC7775562
OpenAlexW3110980731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.